Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different
dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during
maintenance treatment in adult and adolescent participants with schizophrenia. The study will
include male and female participants, 13 to 65 years of age, who have a confirmed diagnosis
of schizophrenia, are clinically stable, and are eligible for risperidone treatment
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.